Shine On You Crazy ...
Health Care: Drugs
POZEN Inc. (POZN: NASDAQ)
$4.96 0.00 | 0.00%
05/21/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -25.28M | 42.34M | 23.07M | -6.86M |
| Operating Gains/Losses | 1.54K | 0.00 | 0.00 | 1.05K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -222.00K | 2.91M | -2.89M | 6.97M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -4.78M | 6.73M | 869.48K | -7.04M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 257.30K | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | -7.20M | -12.34M |
| Other Non-Cash Items | 2.73M | 2.64M | 3.46M | 5.14M |
| Net Cash From Continuing Operations | -26.15M | 56.54M | 17.77M | -15.14M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -26.15M | 56.54M | 17.77M | -15.14M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 24.40M | 0.00 | 32.34M | 37.61M |
| Purchases of Property, Plant & Equipment | -15.82K | -78.57K | -58.05K | -9.06K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -35.92M | -31.81M | -42.43M | -25.34M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -11.54M | 17.29M | -10.15M | 12.26M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 1.31M | 0.00 | 328.19K | 32.70K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -188.53K | -70.26K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 1.12M | -70.26K | 328.19K | 32.70K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -36.57M | 73.76M | 7.95M | -2.84M |
Portfolios with POZN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- UserSm. Magic July 5 13
- ContributorStocks Under-$10 Moving Hig...
- Userwright stocks
- Contributor10 Biotech Stocks Facing FD...
- UserHouxie's stuff
- UserSnoops Millionaire Picks
- UserMMD-05-05-08_END DAY
- Usergrtdane Portfolio 1
Latest POZN Headlines from TheStreet
- Pozen Stock Sees Short Interest Increase 19.5% 05.10.13 | 03:05 pm
- 5 Stocks Under $10 Set to Soar 04.18.13 | 02:04 pm
- POZEN Inc. Stock Downgraded (POZN) 04.03.13 | 05:04 am
- 5 Stocks Under $10 Set to Soar Higher 09.27.12 | 01:09 pm
- POZEN's CEO Presents At Update Conference (Transcript) 08.24.12 | 03:08 pm
- POZEN's CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.01.12 | 04:08 pm
- POZEN Stock Gaps Down On Today's Open (POZN) 06.21.12 | 09:06 am
- POZEN Stock Gaps Down On Today's Open (POZN) 04.27.12 | 11:04 am
- POZEN Stock Hits New 52-Week High (POZN) 04.26.12 | 09:04 am
- POZEN Reaches New 52-Week High (POZN) 04.17.12 | 10:04 am
Press Releases for POZN
- POZEN Submits New Drug Application For PA32540/PA8140 - Business Wire 03.27.13 | 07:03 am
- POZEN To Present At The 25th Annual ROTH Conference - Business Wire 03.07.13 | 07:03 am
- POZEN Reports Fourth Quarter & Year End 2012 Results - Business Wire 03.06.13 | 07:03 am
- POZEN Announces March 6th Webcast Of Fourth Quarter And Year End 2012 Results - Business Wire 02.27.13 | 07:02 am
- POZEN Presents Positive PA32540 Phase 3 Data At The 2013 International Stroke Conference - Business Wire 02.08.13 | 07:02 am
- POZEN To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.19.12 | 07:11 am
- POZEN Announces Positive Results For The PA8140-102 Bioavailability Study - Business Wire 11.15.12 | 04:11 pm
- POZEN Reports Third Quarter 2012 Financial Results And Positive PA32540 Clinical Updates - Business Wire 11.08.12 | 07:11 am
- POZEN Presents Positive PA32540 Pivotal Phase 3 Data At The American Heart Association Scientific Sessions 2012 - Business Wire 11.06.12 | 06:11 pm
- POZEN Announces November 8th Webcast Of Third Quarter 2012 Results And November 6th Presentation Of Phase 3 Results For PA32540 At AHA’s Scientific Sessions 2012 - Business Wire 10.29.12 | 02:10 pm
Partner Headlines for POZN
- Understanding The Market Opportunity For Pozen's Safer Aspirin - Seeking Alpha 01.16.13 | 09:01 am
- Morning Market Losers - Benzinga 06.21.12 | 09:06 am
- Pozen Has No Debt And Plenty Of Resources For 2012 NDA Filing - Seeking Alpha 11.29.11 | 09:11 am
- MICROCAP MOVERS FOR FRIDAY NOVEMBER 25, 2011 - Benzinga 11.25.11 | 04:11 pm
- UPDATE: Brean Murray Maintains Buy, Lowers PT to $7 on Pozen - Benzinga 11.25.11 | 09:11 am
- Financial Breakfast: Morning News Summary for November 25, 2011 - Benzinga 11.25.11 | 09:11 am
- IPO Preview: Horizon Pharma - Seeking Alpha 07.25.11 | 09:07 am
- Pozen Continues Fighting Off Dr. Reddy's Labs - Seeking Alpha 04.26.11 | 09:04 am
- Pozen's Success Will Depend on Execution of Unique Marketing Strategies - Seeking Alpha 03.13.11 | 09:03 am
- Pfizer's Osteoarthritis Drug Runs Into Unique Roadblock - Seeking Alpha 10.04.10 | 08:10 am
